Mark R. Dybul
Mark R. Dybul (born September 23, 1963) is an American diplomat, physician and medical researcher. He served as the executive director of the Global Fund to Fight AIDS, Tuberculosis and Malaria from 2012 until 2017.[2] Since 2021, he has been the CEO of Renovaro Biosciences.[3] Since 2022, he is the Executive Chairman of Purpose Life Sciences.[4]
Mark R. Dybul | |
---|---|
2nd United States Global AIDS Coordinator | |
In office August 2006 – January 2009 Acting: March to August 2006 | |
President | George W. Bush |
Preceded by | Randall L. Tobias |
Succeeded by | Eric Goosby |
Personal details | |
Born | Mark Richard Dybul[1] 1963 (age 59–60) |
Nationality | American |
Education | Georgetown University |
Occupation | Diplomat, Physician |
Biography
Early life and education
Mark Dybul was born September 23, 1963. He received his A.B. (1985) and M.D. (1992) from Georgetown University and completed his residency in internal medicine at the University of Chicago Hospitals (1995) and a fellowship in infectious diseases at the National Institute of Allergy and Infectious Diseases (1998).[5]
Medical and clinical research
Dybul's scientific and clinical research interests have covered the fields of molecular biology, microbiology, virology, pharmacology and especially infectious diseases. He and his colleagues have published in these fields, and he has spoken at medical conferences in infectious diseases.
Career
Dybul started his career by working with AIDS patients in San Francisco, California.[6] Under the presidency of George W. Bush, he was appointed as the United States Global AIDS Coordinator, leading the implementation of the President's Emergency Plan for AIDS Relief from 2006 to 2009.[7][8] However, he is a registered Independent.[6] He is the first out gay ambassador with the rank of Assistant Secretary of State.[9]
Dybul was asked to stay on temporarily during the Barack Obama presidency transition, but was required to resign following the administration change, as he was a political appointee of the Bush administration.[6] On November 15, 2012, he was appointed the next executive director of the Global Fund to Fight AIDS, Tuberculosis and Malaria.[10] His selection as executive director by the Global Fund's board during its 28th meeting in Geneva was met with praise from both donors and the development community. World Bank President Jim Yong Kim called Dybul's appointment a "superb choice for a crucial role".[11] In an interview published in the Global Fund's digital newsletter, Dybul said his role as the Global Fund's new head "will be to maintain the strong forward trajectory of the Fund in order to end the three diseases".[12] He assumed his role of head of the Global Fund in February 2013.
Dybul is a professor in the department of medicine at the Medical Center of Georgetown University and the codirector of the Center for Global Health Practice and Impact. He is a member of the Global Health Initiative faculty committee.[13] From 2020 until 2022, Dybul served as a member of the Independent Panel for Pandemic Preparedness and Response, a group examining how the World Health Organization and countries handled the COVID-19 pandemic, co-chaired by Helen Clark and Ellen Johnson Sirleaf.[14] In the preparations for the Global Health Summit hosted by the European Commission and the G20 in May 2021, he was a member of the event's High Level Scientific Panel.[15]
Dybul has been an executive vice-chairman of Enochian Biosciences, a US biotechnology company, since 2019, before being appointed as its CEO in 2021.[16] Enochian changed its name to Renovaro Biosciences on August 14, 2023.
References
- "Presidential Nomination". George W. Bush White House Archives. Retrieved 2021-01-07.
- "Dr. Mark Dybul, former Executive Director of the Global Fund and U.S. Global AIDS Coordinator, Appointed to the Board of Directors of MSH". Management Sciences for Health. Management Sciences for Health. 2018-04-27. Retrieved 2019-09-07.
- "Renovaro BioSciences Inc. | About - Board of Directors - Person Details". renovarobio.com.
- "About Us". purposelifesciences.com. Retrieved 2023-08-20.
- "Ambassador Mark R. Dybul". georgewbush-whitehouse.archives.gov.
- After Departure, No Leader for U.S. AIDS Program. The New York Times. January 30, 2009.
- "Search for the Global Fund Executive Director - the Global Fund to Fight AIDS, Tuberculosis and Malaria". Archived from the original on 2012-11-09. Retrieved 2012-11-23.
- Varmus, Harold (1 December 2013). "Making PEPFAR". Science & Diplomacy. 2 (4).
- Hammond, William M. (2010-09-01). "U.S. Department of State: Office of the Historian". Journal of American History. 97 (2): 592–593. doi:10.1093/jahist/97.2.592. ISSN 0021-8723 – via The Journal of American History.
- http://www.sacbee.com/2012/11/15/4988816/global-fund-appoints-mark-dybul.html
- "Statements of Support on Executive Director Appointment". Archived from the original on December 26, 2012.
- "News Flash Special: Interview with Mark Dybul". Archived from the original on December 3, 2012.
- "Mark Dybul".
- Stephanie Nebehay and Kate Kelland (September 3, 2020), Pandemic review panel named, includes Miliband, ex Mexican president Reuters.
- Global Health Summit: Panel of Scientific Experts European Commission.
- Bioscience, Enochian (2021-07-20). "Enochian BioSciences Names The Hon. Dr. Mark Dybul as Chief Executive Officer". GlobeNewswire News Room (Press release). Retrieved 2023-02-06.
- "Team".
- Georgetown Global Forum Profile Archived 2009-04-22 at the Wayback Machine
- Accordia Global Health Foundation.
- "DR. MARK DYBUL, FORMER EXECUTIVE DIRECTOR OF THE GLOBAL FUND AND U.S. GLOBAL AIDS COORDINATOR, APPOINTED TO THE BOARD OF DIRECTORS OF MSH". Management Sciences for Health. Archived from the original on 2021-12-08.
- "The Hon. Mark Dybul".
- "Team".
- "Our Team".
- "Mark Dybul | Global Health Corps". 16 November 2015.
- Wright, Robin (16 April 2007). "At State, a Friendlier Workplace". The Washington Post. p. A15.
- Schenke, Leann (6 July 2020). "Kent Cultural Alliance adds two board members, elects new chair". Kent County News. Retrieved 28 November 2022.